Gonadorelin
Also known as: GnRH, LH-RH, LHRH, Gonadotropin-Releasing Hormone, Gonadorelin Hydrochloride, Gonadorelin Acetate, Gonadorelin Diacetate Tetrahydrate, Factrel
Peptide hormone / Gonadotropin-Releasing Hormone (GnRH) agonist (native decapeptide)
What it is
Gonadorelin is the synthetic form of the natural hormone that triggers the pituitary to release sex hormones; it's used in fertility treatment and diagnostic testing. It works by pulsing the pituitary to stimulate the hormones that drive testosterone and estrogen production. Not FDA-approved as a standalone therapeutic drug; banned by WADA in sport.
The scientific side
Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH), synthesized and released by the hypothalamus. It regulates the production and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the anterior pituitary (adenohypophysis). When administered parenterally, it was initially used diagnostically as a test of pituitary reserve of LH and FSH; subsequently, native GnRH was used therapeutically to treat hypothalamic hypogonadal and infertility states. In male athletes, its misuse triggers testosterone increase, which is why WADA has banned it. In aquaculture studies, gonadorelin has been shown to increase circulating concentrations of sex steroids (17β-estradiol, 17α-hydroxyprogesterone, testosterone) and modulate gonadotropin expression, and was associated with ovulation in female tambaqui fish. In dairy cattle, gonadorelin stimulates LH release leading to ovulation, and its effects are dose-dependent.
Class: Peptide hormone / Gonadotropin-Releasing Hormone (GnRH) agonist (native decapeptide)
Administration & storage
- Administration
- Intravenous (i.v.) — used in diagnostic GnRH stimulation tests in humans (PMID: 3103350)Intravenous — case report of anaphylaxis after i.v. gonadorelin acetate (PMID: 26197466)Intranasal spray — used for cryptorchidism treatment in children (PMID: 2572057; PMID: 35691791)Pulsatile subcutaneous/intravenous infusion pump — used for hypogonadotropic hypogonadism treatment in men (PMID: 30569789; PMID: 25131486)Infusion pump (IgE-mediated hypersensitivity case) — pump delivery reported in female patient with hypogonadotropic hypogonadism (PMID: 2653043)Veterinary intramuscular or i.v. injection (not specified route) — used in Ovsynch cattle protocols (PMID: 25979657; PMID: 41698585; PMID: 39603499)
- Storage
- No storage conditions for gonadorelin are explicitly described in the reviewed abstracts.
- Cautions
- Severe anaphylaxis has been reported following intravenous gonadorelin acetate administration; gonadorelin should only be administered in a setting equipped to manage systemic reactions.,IgE-mediated hypersensitivity (wheal-and-flare at injection sites, elevated IgE antibodies to gonadorelin) was reported in a patient receiving long-term gonadorelin hydrochloride (Factrel) via infusion pump.,Skin allergic erythema scleroma was a common reported side effect at the site of the pulsatile gonadorelin pump in men with CHH.,Long-term treatment with gonadorelin agonist analogs (e.g., triptorelin) has been associated with significant bone loss/osteoporosis; this adverse effect warrants monitoring (PMID: 17971105; PMID: 17290340).,Gonadorelin is listed as a banned substance by WADA; its use by athletes for testosterone enhancement is considered doping.,Sterile technique is essential for any injectable peptide preparation to prevent contamination and infection at injection sites.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Listed as a banned substance in sports per WADA (PMID: 35028691; PMID: 36858006)
Not stated in reviewed literature — requires manual verification
What it's studied for
- Diagnosis of hypothalamic-pituitary function / pituitary reserve testing (GnRH stimulation test) Human observational
- 80 µg gonadorelin administered intravenously to women with normal cycles and secondary amenorrhea provoked typical gonadotropin (LH/FSH) release, with LH peak at 30–60 minutes. The test was described as a good complement to progesterone and clomiphene tests. PMID 3103350 Vesper et al. Zentralblatt fur Gynakologie (1986)
- In 292 girls with advanced breast development, the GnRH stimulation test differentiated central precocious puberty (CPP) from premature thelarche (PT). LH/FSH ratio >0.9 at 15 min had 80.1% sensitivity and 90.8% specificity for CPP; blood sample at 60 min was not necessary. PMID 15476332 Jiang et al. Journal of Zhejiang University. Medical sciences (2004)
- In 865 ICPP girls, higher BMI was associated with lower LH response to GnRH stimulation testing. Obese girls had lower peak LH and LH/FSH ratio compared to normal-weight girls. BMI should be considered when interpreting GnRH stimulation tests. PMID 25645648 Fu et al. Obesity (Silver Spring) (2015)
- Treatment of hypogonadotropic hypogonadism (HH) in men — induction of spermatogenesis Human observational
- In 28 azoospermic CHH males, pulsatile gonadorelin pump (PGP) induced spermatogenesis significantly earlier than cyclical gonadotropin therapy (median 6 vs. 14 months; p=0.01). Spermatogenesis occurred in 90% of PGP group and 83.3% of CGT group (non-significant difference). Skin allergic erythema scleroma was a common PMID 30569789 Zhang et al. American Journal of Men's Health (2019)
- Two cases of hypogonadotropic hypogonadism caused by pituitary stalk interruption syndrome treated with pulse infusion of gonadorelin via micropump. After 12 weeks, androgen deficiency improved and gonadotropin levels increased. PMID 25131486 Shao et al. Journal of Peking University. Health sciences (2014)
- Neoadjuvant hormonal treatment in cryptorchidism (undescended testis) Human RCT
- Prospective RCT in 36 infants with unilateral cryptorchidism (21 GnRH, 15 control). Intranasal gonadorelin treatment showed no significant effect on penile size, testicular volume, or hormonal levels at orchidopexy compared to controls. Mid-term safety was acceptable. PMID 35691791 Fiala et al. Journal of Pediatric Urology (2022)
- In 94 outpatients (mean age 4.16 years) with mono- or bilateral cryptorchidism, intranasal gonadorelin was administered for 4 weeks. Authors concluded gonadorelin has a role in treating cryptorchidism and suggested it should be first-choice treatment. PMID 2572057 Beretta & Zanollo. Archivio italiano di urologia (1989)
- Timed artificial insemination (AI) protocols in dairy cattle (Ovsynch-based programs) Animal studies only
- In 3,938 Holstein cows using Ovsynch-based programs, no significant difference in pregnancy per AI (P/AI) was found between gonadorelin diacetate tetrahydrate (100 µg) and gonadorelin hydrochloride (100 µg). Other factors (season, somatic cell count, parity) affected P/AI. PMID 25979657 Poock et al. Theriogenology (2015)
- In 6,621 lactating dairy cows, 200 µg gonadorelin hydrochloride at the first GnRH of breeding Ovsynch improved P/AI (51.8% vs. 48.6%), ovulatory response (83.0% vs. 70.8%), and LH peak compared with 100 µg, with the greatest benefit in multiparous cows. PMID 41698585 Lima et al. Journal of Dairy Science (2026)
- In 2,111 services in 1,438 Holstein cows, increasing GnRH dose from 100 µg to 200 µg at Resynch-25 initiation increased ovulatory response (48.0% vs. 36.1%) but did not improve overall fertility. An extra GnRH at 56 h tended to decrease P/AI. PMID 39603499 Leão et al. Journal of Dairy Science (2025)
- Induction of ovulation in aquaculture (tambaqui fish) Animal studies only
- Gonadorelin at 60 µg/kg body weight in mature female tambaqui increased sex steroid concentrations (E2, 17α-OHP, testosterone) and induced ovulation in 6/9 (67%) treated females vs. 0% controls. Gonadorelin decreased fshβ expression but had no significant effect on lhβ expression. PMID 40645558 Oliveira et al. Comparative Biochemistry and Physiology Part B (2025)
- Anti-doping detection (analytical methods development) In vitro only
- A biomimetic ELISA (BELISA) using molecularly imprinted polymer (MIP)-coated microplates achieved a detection limit of 277 pmol/L for gonadorelin in urine samples, with good reproducibility (CV% = 5.24%). Results validated by mass spectrometry. PMID 35028691 Torrini et al. Analytical and Bioanalytical Chemistry (2022)
- Review of analytical methods (chromatography, immunochemistry, affinity sensing) for gonadorelin detection in anti-doping context. Aptamers and molecular imprinted polymers (MIPs) described as leading biomimetic approaches. PMID 36858006 Torrini et al. Journal of Pharmaceutical and Biomedical Analysis (2023)
- Radiopharmaceutical imaging (67Ga-labeled gonadorelin for tumor imaging) Animal studies only
- In rats, biodistribution of 67Ga-cDTPA-gonadorelin showed high breast uptake and low muscle/blood uptake. Extrapolated estimated effective absorbed dose in humans from 185 MBq injection: 5.26 mGy whole body; highest in lungs (2.73 mSv), bladder wall (1.59 mSv), liver (0.80 mSv). PMID 21068688 Shanehsazzadeh et al. Nuclear Medicine Communications (2011)
- Treatment of endometriosis, uterine leiomyoma, prostate cancer, and precocious puberty (GnRH agonist analogs) Mixed
- Review: native GnRH (gonadorelin) used therapeutically for hypothalamic hypogonadism and infertility. Long-acting potent analogs developed to suppress pituitary gonadotropins; used parenterally and intranasally for prostate/breast carcinoma, endometriosis, uterine leiomyomata, precocious puberty, and nontumorous ovaria PMID 1835275 Pace et al. American Family Physician (1991)
Safety signals
- Severe anaphylaxis (loss of consciousness, tonic seizures) following intravenous gonadorelin acetate administration in an 8-year-old girl with central precocious puberty; recovered within 30 minutes after epinephrine, diphenhydramine, and fluids. PMID 26197466
- IgE-mediated hypersensitivity reaction (wheal-and-flare at injection sites) during long-term gonadorelin hydrochloride (Factrel) infusion pump therapy in a female patient with hypogonadotropic hypogonadism. PMID 2653043
- Significant bone loss (reduced bone density/osteoporosis) reported as a side effect of long-term treatment with long-acting gonadorelin agonist triptorelin in a 35-year-old male with paraphilia. PMID 17971105
- Significant bone loss (reduced bone density/osteoporosis) reported with long-acting gonadorelin treatment in a 35-year-old male with paraphilia (Dutch case report). PMID 17290340
- Skin allergic erythema scleroma at the site of pulsatile gonadorelin pump was a common side effect in men with congenital hypogonadotropic hypogonadism treated with PGP. PMID 30569789
- Facial acne and breast tenderness noted as more frequent in CHH men receiving cyclical gonadotropin therapy (associated with higher testosterone levels); not directly attributable to gonadorelin, but reported in comparative study. PMID 30569789
- Gonadorelin analogs combined with anti-androgens for prostate cancer bone metastasis have been associated with possible osteoporosis induction. PMID 2532342
Contraindications
- Known or suspected hypersensitivity to gonadorelin or related peptides. A case of severe anaphylaxis after i.v. gonadorelin acetate in a child receiving triptorelin treatment indicates that cross-reactivity and severe allergic responses are possible. PMID 26197466
- Prior documented IgE-mediated hypersensitivity to gonadorelin hydrochloride; the reviewed case required discontinuation of luteinizing hormone-releasing hormone therapy. PMID 2653043
Protocol
100 mcg subcutaneous injection, twice weekly (e.g. monday and thursday). Cycle: ongoing, concurrent with trt cycle.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous (i.v.) | 80 µg (two doses, 120 minutes apart) | Single diagnostic test | human | Research PMID 3103350 |
| Pulsatile infusion pump (subcutaneous/intravenous, not specified) | Pulsatile gonadorelin pump (PGP); dose not specified in abstract | Up to 24 months | human | Research PMID 30569789 |
| Not specified (veterinary injection) | 100 µg (2 mL), either gonadorelin hydrochloride or gonadorelin diacetate tetrahydrate | Single injection (within Ovsynch protocol) | animal | Research PMID 25979657 |
| Not specified (veterinary injection) | 100 µg (2 mL) or 200 µg (4 mL) gonadorelin hydrochloride (Factrel; Zoetis) | Single injection (within Double-Ovsynch protocol) | animal | Research PMID 41698585 |
| Not specified (veterinary injection) | 100 µg or 200 µg GnRH | Single or twice (56 h apart) within Resynch-25 protocol | animal | Research PMID 39603499 |
| Not specified | 60 µg/kg body weight | Single treatment | animal | Research PMID 40645558 |
| Intravenous | 185 MBq (67Ga-cDTPA-gonadorelin) | Single injection (biodistribution study) | animal | Research PMID 21068688 |
| subcutaneous injection | 100 mcg | twice weekly (e.g. Monday and Thursday) · ongoing, concurrent with TRT cycle | male TRT users seeking to maintain testicular size and endogenous LH/FSH signaling | [Community] |
| subcutaneous injection | 100 mcg | three times weekly (e.g. Monday, Wednesday, Friday) · ongoing, concurrent with TRT cycle | male TRT users on more frequent injection schedules (EOD or 3x/week testosterone protocols) | [Community] |
| subcutaneous injection | 100 mcg | daily · ongoing, concurrent with TRT | male TRT users on daily testosterone protocols (e.g. daily subcutaneous testosterone) | [Community] |
| subcutaneous injection | 250 mcg | twice weekly · ongoing, concurrent with TRT or post-cycle | male TRT or post-cycle users wanting stronger LH/FSH stimulation | [Community] |
| subcutaneous injection | 500 mcg | twice weekly · 4–12 weeks (post-cycle recovery) | anabolic steroid users in post-cycle therapy (PCT) seeking axis restart | [Community] |
| intranasal | 100 mcg | twice weekly · ongoing, concurrent with TRT | male TRT users seeking needle-free administration | [Community] |
| subcutaneous injection | 100 mcg | twice weekly · ongoing | males with secondary hypogonadism seeking fertility preservation or restoration | [Community] |
| subcutaneous injection | 25 mcg | daily · ongoing, concurrent with TRT | male TRT users adopting low-dose, high-frequency protocols to mimic physiological GnRH pulsatility | [Community] |
All studies (20)
- PMID 2572057 Human RCT
Neoadjuvant hormonal treatment in cryptorchidism (undescended testis) - PMID 35691791 Human RCT
Neoadjuvant hormonal treatment in cryptorchidism (undescended testis) - PMID 3103350 Human observational
Diagnosis of hypothalamic-pituitary function / pituitary reserve testing (GnRH stimulation test) - PMID 15476332 Human observational
Diagnosis of hypothalamic-pituitary function / pituitary reserve testing (GnRH stimulation test) - PMID 25131486 Human observational
Treatment of hypogonadotropic hypogonadism (HH) in men — induction of spermatogenesis - PMID 25645648 Human observational
Diagnosis of hypothalamic-pituitary function / pituitary reserve testing (GnRH stimulation test) - PMID 30569789 Human observational
Treatment of hypogonadotropic hypogonadism (HH) in men — induction of spermatogenesis - PMID 1835275 Mixed
Treatment of endometriosis, uterine leiomyoma, prostate cancer, and precocious puberty (GnRH agonist - PMID 2532342
Gonadorelin analogs combined with anti-androgens for prostate cancer bone metastasis have been associated with possible osteoporosis induction. - PMID 2653043
IgE-mediated hypersensitivity reaction (wheal-and-flare at injection sites) during long-term gonadorelin hydrochloride (Factrel) infusion pump therapy in a fema - PMID 17290340
Significant bone loss (reduced bone density/osteoporosis) reported with long-acting gonadorelin treatment in a 35-year-old male with paraphilia (Dutch case repo - PMID 17971105
Significant bone loss (reduced bone density/osteoporosis) reported as a side effect of long-term treatment with long-acting gonadorelin agonist triptorelin in a - PMID 21068688 Animal studies only
Radiopharmaceutical imaging (67Ga-labeled gonadorelin for tumor imaging) - PMID 25979657 Animal studies only
Timed artificial insemination (AI) protocols in dairy cattle (Ovsynch-based programs) - PMID 26197466
Severe anaphylaxis (loss of consciousness, tonic seizures) following intravenous gonadorelin acetate administration in an 8-year-old girl with central precociou - PMID 35028691 In vitro only
Anti-doping detection (analytical methods development) - PMID 36858006 In vitro only
Anti-doping detection (analytical methods development) - PMID 39603499 Animal studies only
Timed artificial insemination (AI) protocols in dairy cattle (Ovsynch-based programs) - PMID 40645558 Animal studies only
Induction of ovulation in aquaculture (tambaqui fish) - PMID 41698585 Animal studies only
Timed artificial insemination (AI) protocols in dairy cattle (Ovsynch-based programs)